An In-vivo Study to Evaluate the Onset of Relief from Ibuprofen, Placebo and Occlusal Splint in Patients with Acute Myalgia in Muscles Related to Temporomandibular Joint: A Comparative Pilot Study


  • MK Bhavnagar University, Department of Prosthodontics and Crown and Bridge, MP Dental College and Oral Research Institute, Vadodara, Gujarat, 390011, India


Purpose: The treatment priority in management of Temporomandibular Joint (TMJ) pain is directed towards the causative factor along with symptomatic treatment. In this process many times psychological aspect is overlooked. Hence with this pilot study, importance of psychological aspect of Temporomandibular Joint Disorder (TMD) is emphasised. Methods and Material: 15 patients suffering from pain in TMD region who qualify under myalgia pain in DC/TMD Axis I category were selected. Patients were divided into 3 groups; Ibuprofen, placebo and occlusal splint with 5 patients in each group. Pain assessment was done at the first visit, 7th day visit and 14th day visit using a VAS scale. Statistical Analysis Used: Friedman Test was applied to determine overall relief from pain in the three groups. Wilcoxon sign rank test evaluated pain relief between each time interval. Kruskal Wallis Test compared different groups for relief from pain at each time interval. Key Finding: Wilcoxon sign rank test showed a significant pain relief in all three groups from I day to I follow up day and I day to II follow up day. However Pain relief from I follow up to II follow up day was significant only in placebo group. Conclusions: Management of TMD myalgia requires a comprehensive understanding of physical and psychological aspect. This will aid us in formulating a treatment plan comprising pharmacotherapy, placebo or physical therapy or combination of any of these.


Myalgia, NSAIDs, Occlusal Splint, Placebo, Temporomandibular Disorder

Full Text:


Romero-Reyes M and Uyanik JM. Orofacial pain management: Current perspectives. J Pain Res. 2014; 7:99–115. PMid: 24591846 PMCid: PMC3937250.

Sidebottom AJ, Farook S, Cascarini L. Current management of Temporomandibular Joint (TMJ) Disease. J Arthiritis 2014 3:3.

Schiffman E and Ohrbach R. Diagnostic criteria for Temporomandibular Disorders (DC/TMD) for clinical and research application. Journal of Oral Facial Headache. 2014; 28:6–27.

Okeson JP. Management of Temporomandibular Disorders and occlusion. 6th ed. St. Louis, MO: CV Mosby, 2008.

Dionne RA. Pharmacologic treatments for Temporomandibular Disorders. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997; 83(1):134–42. S1079-2104(97)90104-9

Ouanounou A, Goldberg M and Haas DA. Pharmacotherapy in Temporomandibular Disorders: A Review. J Can Dent Assoc. 2017; 83:h7.

Singer EJ, Sharav Y, Dubner R and Dionne RA. The efficacy of diazepam and ibuprofen in the treatment of chronic myofascial orofacial pain. Pain. 1987; 4:S83.

Pramod GV, Shambulingappa P, Shashikanth MC and Lele S. Analgesic efficacy of diazepam and placebo in patients with Temporomandibular Disorders: A double blind randomized clinical trial. IJDR. 2011; 22(3):404–9. PMid: 22048580.

Klasser GD and Greene CS. Oral appliances in the management of Temporomandibular Disorders. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009; 107(2):212–23. PMid: 19138639.

Ouanounou A, Goldberg M and Haas DA. Pharmacologic considerations in the management of Temporomandibular Disorders. J Can Dent Assoc. 1995; 61(2):105–9.

Ta LE and Dionne RA. Treatment of painful Temporomandibular Joints with a cyclooxygenase-2 inhibitor: A randomized placebo-controlled comparison of celecoxib to naproxen. Pain. 2004; 111(1-2):13–21. PMid: 15327804.

Haas DA. Adverse drug interactions in dental practice: Interactions associated with analgesics, Part III in a series. J Am Dent Assoc. 1999; 130(3):397–407. PMid: 10085663.

Varoli FK, Pita MS, Sato S and Issa JPM. Analgesia evaluation of 2 NSAID drugs as adjuvant in management of chronic Temporomandibular Disorders. Scientific World Journal. 2015; 359152. PMid: 25874243 PMCid: PMC4385689.

Friction J. Myogenous TMDs: Diagnostic and management considerations. DCNA 2007; 51(1):61–83. PMid: 17185060.

Clark GT, Beemsterboer PL and Rugh JD. Nocturnal electromyographic evaluation of MPDS in patients undergoing occlusal splint therapy. J Am Dsent Assoc. 199; 99(4):607. PMid: 292717.

Dube C, Rompre PH, Manzini C, Guitard F, de Grandmont P and Lavigne GJ. Quantitative polygraphic controlled study on efficacy and safety of oral splint devices in tooth-grinding subjects. J Dent Res. 2004; 83(5):398–403. PMid: 15111632.

Jyoti RSB and Devi P. Oral splint for Temporomandibular Joint disorders with revolutionary fluid system. Dent Res J (Isfahan). 2013 May-Jun; 10(3):307–13.

Manfredini D, Landi N, Bandettini Di Poggio A, Dellosso L and Bosco M. A critical review on the importance of psychological factors in Temporomandibular Disorders. Minerva Stomatol. 2003; 52(6):321–30.

Murray GM and Peck CC. Orofacial pain and jaw muscle activity: A new model. J Orofac Pain. 2007; 21:263–78.

Cairns BE. Pathophysiology of TMD pain - basic mechanisms and their implications for pharmacotherapy. Journal of Oral Rehabilitation. 2010; 37:391–410. PMid: 20337865.

Gale EM and Dixon DC. A simplified psychologic questionnaire as a treatment planning aid for patients with Temporomandibular Joint Disorders. J Prosthet Dent. 1989; 61(2):235–8.

Pereira LJ, Pereira-Cenci T, Pereira SM, Del Bel Cury AA, Ambrosano GMB and Pereira AC. Psychological factors and the incidence of Temporomandibular Disorders in early adolescence. Braz Oral Res. 2009; 23(2):155–60. PMid: 19684950.

Ekberg E. Treatment of Temporomandibular Disorders of arthrogeneous origin. Controlled double-blind studies of a non-steroidal anti-inflammatory drug and a stabilization appliance. Swed Dent J Suppl. 1998; 131:1–57.

Beck FM. Placebos in dentistry: Their profound potential affects. JADA. 1977; 95:1122–6. PMid: 271675.

Beecher HK. The powerful placebo. JAMA. 1955; 159(17):1602–6. PMid: 13271123.


  • There are currently no refbacks.